Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Great Point Partners Jeffrey Jay And David Kroin | 4,973,840 | $9,549,773 | 5.06% | |
| 2. | Renaissance Technologies Jim Simons | 4,005,827 | $7,691,188 | +5% | 0.01% |
| 3. | Citadel Investment Group Ken Griffin | 3,646,909 | $7,002,066 | +164% | 0% |
| 4. | AIGH Investment Partners Orin Hirschman | 2,925,000 | $5,616,000 | 2.32% | |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,485,578 | $4,772,310 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.43 | 5,800 | $19,894.00 | 29,731 | 2019-11-20 | Filing | |
| $3.52 | 15,000 | $52,800.00 | 28,700 | 2019-11-20 | Filing | |
| $3.58 | 27,000 | $96,660.00 | 37,000 | 2019-11-20 | Filing | |
| $3.44 | 50,000 | $172,000.00 | 887,732 | 2019-11-20 | Filing | |
| $3.41 | 50,000 | $170,500.00 | 63,700 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.67 | 41,314 | $151,622.38 | 503,586 | 2025-06-30 | Filing | |
| $4.01 | 15,000 | $60,150.00 | 266,914 | 2025-06-09 | Filing | |
| $3.53 | 13,334 | $47,069.02 | 266,914 | 2025-06-04 | Filing | |
| $1.83 | 46,409 | $84,928.47 | 2,557,921 | 2025-03-03 | Filing | |
| $1.83 | 7,144 | $13,073.52 | 809,090 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,332,163 | $29,437,752 | 0% | |
| 2. | 12,685,803 | $24,356,741 | 0% | |
| 3. | 350,413 | $20,496,484 | 0.01% | |
| 4. | 6,805,807 | $13,067,149 | 0% | |
| 5. | 5,030,740 | $9,661,509 | 0% |
News See All
13 Stocks Under $5 With High Upside Potential
On July 1, Ralph Schlosstein, Evercore chairman emeritus and BlackRock co-founder, appeared on CNBC's 'Closing Bell Overtime' to discuss his outlook for markets heading into the second half of 2025.
Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is among the best growth stocks to invest in for the next 5 years. Akebia Therapeutics, Inc.
12 Small Cap Stocks with High Upside Potential
The trade war saga between the U.S. and China appears to be nearing a conclusion, as China’s Ministry of Commerce shared details on the trade deal on June 27.
Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 12 Small Cap Stocks with High Upside Potential.
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts.
10 Best Healthcare Penny Stocks to Buy According to Analysts
According to the Centers for Medicare & Medicaid Services (CMS), the US healthcare sector accounted for approximately 17.6% of GDP in 2023.
15 Best Growth Stocks to Invest in for the Next 5 Years
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
